The Many Hats of Clay Siegall
Clay B. Siegall, PhD, wears many hats throughout his career, acting as Co-founder, President, CEO, and Chairman of the Board at Seattle Genetics.
Seattle Genetics is a biotechnology company, founded in 1997, with it’s mind set on developing and commercializing innovative medical solutions using monoclonal antibody-based therapies for cancer treatment.
This technology is designed to utilize the unique targeting capabilities of monoclonal antibodies to send cell-killing agents directly to cancer cells.
Seattle Genetics has established itself as an industry leader in Antibody Drug Conjugates (ADCs), and works diligently to create antibody-based therapies designed to address unmet medical needs.
Dr. Siegall is a scientist by training, and has established Seattle Genetics on a firm foundation of scientific innovations, and a rigorous research ethic.
Clay Siegall began his college career at the University of Maryland, where he earned his Bachelor in Science. He then went on to The George Washington University where he received his PhD.
Prior to co-founding Seattle Genetics, Dr. Siegall worked with Bristol-Meyers Squibb Pharmaceutical Research Institute
Today, in addition to the many hats he wears at Seattle Genetics, Dr. Siegall also serves as Director at Alder Biopharmaceuticals, Inc, in addition to serving as Director at Ultragenyx Pharmaceutical, Inc.
Remaining a very present force in the scientific community, Dr. Siegall has authored as many as sixty-seven scientific papers, and serves on the Editorial Board of no less than three scientific publications, in addition to being a member on the Board of Scientific Counselors for the Cancer Treatment Research Foundation and holder of nine patents.
In 1995, Dr. Siegall was the recipient of the Pierce Award for his efforts in the field of targeted toxins, and in 2002 he became a finalist in the Ernst & Young Pacific Northwest Entrepreneur of the Year award in the category of healthcare.